Literature DB >> 2212993

Prediction and identification of a T cell epitope in the fusion protein of measles virus immunodominant in mice and humans.

C D Partidos1, M W Steward.   

Abstract

Amino acid residues 288 to 302 of the fusion protein of measles virus were predicted by a variety of methods to represent a putative T cell epitope. This sequence was synthesized and the peptide was injected into mice of six inbred strains to test this possibility. Lymphocytes from peptide-immunized mice from all six H-2 disparate strains were able to mount a proliferative response following in vitro culture with the peptide. In addition, lymphocytes from three strains also proliferated in the presence of live measles virus. The peptide also behaved as a B cell epitope in that immunization with free peptide in adjuvant resulted in anti-peptide antibody production in all mouse strains. However, these antibodies did not react with the virus in either a solid-phase immunoassay or a virus neutralization assay. Peripheral blood lymphocytes from 10 laboratory personnel with a prior history of exposure to measles virus were tested in a proliferation assay with the peptide and with the virus. Lymphocytes from all 10 individuals proliferated in response to culture with the virus and those from eight responded to the peptide. These results give further support to the concept of permissive interaction of antigenic peptides with a wide range of class II major histocompatibility complex molecules both in mice and man and indicate the possibility of designing peptides that could be used as components of a synthetic vaccine for use in man.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2212993     DOI: 10.1099/0022-1317-71-9-2099

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  21 in total

1.  Enhancement of the antibody response to flavivirus B-cell epitopes by using homologous or heterologous T-cell epitopes.

Authors:  J T Roehrig; A J Johnson; A R Hunt; B J Beaty; J H Mathews
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

2.  Antibody responses to non-immunogenic synthetic peptides induced by co-immunization with immunogenic peptides.

Authors:  C D Partidos; O E Obeid; M W Steward
Journal:  Immunology       Date:  1992-10       Impact factor: 7.397

3.  Induction of measles virus-specific cytotoxic T-cell responses after intranasal immunization with synthetic peptides.

Authors:  C D Partidos; P Vohra; M W Steward
Journal:  Immunology       Date:  1996-02       Impact factor: 7.397

4.  Identification of an immunodominant neutralizing and protective epitope from measles virus fusion protein by using human sera from acute infection.

Authors:  S F Atabani; O E Obeid; D Chargelegue; P Aaby; H Whittle; M W Steward
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

5.  Mapping major and minor T-cell epitopes in vitro and their immunogenic or tolerogenic effect in vivo in non-human primates.

Authors:  P R Walker; R Smerdon; J Haron; T Lehner
Journal:  Immunology       Date:  1993-10       Impact factor: 7.397

6.  Human HLA class I- and HLA class II-restricted cloned cytotoxic T lymphocytes identify a cluster of epitopes on the measles virus fusion protein.

Authors:  R S van Binnendijk; J P Versteeg-van Oosten; M C Poelen; H F Brugghe; P Hoogerhout; A D Osterhaus; F G Uytdehaag
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

7.  Human T-lymphotropic virus type 1 peptides in chimeric and multivalent constructs with promiscuous T-cell epitopes enhance immunogenicity and overcome genetic restriction.

Authors:  M D Lairmore; A M DiGeorge; S F Conrad; A V Trevino; R B Lal; P T Kaumaya
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

8.  Ex vivo analysis of cytotoxic T lymphocytes to measles antigens during infection and after vaccination in Gambian children.

Authors:  A Jaye; A F Magnusen; A D Sadiq; T Corrah; H C Whittle
Journal:  J Clin Invest       Date:  1998-12-01       Impact factor: 14.808

9.  Identification and characterization of novel, naturally processed measles virus class II HLA-DRB1 peptides.

Authors:  Inna G Ovsyannikova; Kenneth L Johnson; David C Muddiman; Robert A Vierkant; Gregory A Poland
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

10.  Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors.

Authors:  Pravin T P Kaumaya; Kevin Chu Foy; Joan Garrett; Sharad V Rawale; Daniele Vicari; Jennifer M Thurmond; Tammy Lamb; Aruna Mani; Yahaira Kane; Catherine R Balint; Donald Chalupa; Gregory A Otterson; Charles L Shapiro; Jeffrey M Fowler; Michael R Grever; Tanios S Bekaii-Saab; William E Carson
Journal:  J Clin Oncol       Date:  2009-09-14       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.